Skip to main content
Uni-Bio Science Group Limited logo

Uni-Bio Science Group Limited — Investor Relations & Filings

Ticker · 690 HKEX Manufacturing
Open in API
Filings indexed 1,066 across all filing types
Latest filing 2020-12-15 Regulatory Filings
Country HK Hong Kong
Listing HKEX 690

About Uni-Bio Science Group Limited

http://www.uni-bioscience.com

Uni-Bio Science Group Limited is an innovative biopharmaceutical enterprise specializing in the R&D, manufacturing, and sales of biological and chemical pharmaceutical products. The company's core strategy centers on regenerative medicine, focusing on therapeutic areas such as endocrinology, dermatology, and ophthalmology. Key research pipelines address bone and muscle regeneration (including osteoporosis), skin and tissue repair (burns, chronic wounds, and medical aesthetics), and ocular regeneration (corneal damage and macular degeneration). Unique technological platforms include the ECO-KSFA® micro-protein manufacturing system for high-stability biologics and smart hydrogel technology for advanced tissue engineering and targeted delivery solutions.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION GRANTED MARKETING APPROVAL FOR BOSHUTAI (ACARBOSE TABLETS) IN CHINA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of Uni-Bio Science Group Limited regarding the marketing approval granted by the National Medical Products Administration (NMPA) for a new drug product, BOSHUTAI (Acarbose Tablets), in China. It includes details about the approval date, manufacturing inspection, and the company's plans for commercialization. The document is relatively short (3530 characters) and does not contain any financial statements, detailed financial performance data, or comprehensive management discussion. It is an announcement of a regulatory approval event rather than a financial report or detailed management report. There is no indication that this is a full annual or interim report, audit report, earnings release, or other financial filing. It also does not fit into categories like board changes, voting results, or legal proceedings. Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2020-12-15 English
VOLUNTARY ANNOUNCEMENT UNI-BIO SCIENCE GROUP RECEIVES BE CERTIFICATION FOR PINUP (VORICONAZOLE TABLETS) BY THE NMPA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Uni-Bio Science Group Limited regarding the receipt of BE (Bioequivalence) certification for a drug product from the National Medical Products Administration (NMPA). It is an announcement of a regulatory approval related to product certification and market positioning, not a financial report, management change, or shareholder meeting material. The document is relatively short (3970 characters) and serves as a news update rather than a detailed report or filing. It does not contain financial statements, earnings data, or detailed governance information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-12-09 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2020
Capital/Financing Update Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related activities for the month ended 30 November 2020. The content is focused on share capital changes and securities movements rather than financial performance, management commentary, or regulatory certifications. It is a regulatory disclosure about share capital and securities movements, typical of a capital or financing update. The document is lengthy (15,000 characters) and contains detailed tables of share movements, which aligns with a Capital/Financing Update rather than a simple announcement or a full financial report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-12-01 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and pertains to changes in issued share capital and share buybacks by Uni-Bio Science Group Limited. It includes detailed information on shares repurchased and cancelled, confirmations regarding compliance with listing rules, and specifics about share capital changes. The content focuses on reporting share repurchase activities and changes in capital rather than financial results, management changes, or other report types. This matches the description of 'Transaction in Own Shares' filings, which report company buybacks or sales of its own shares. The document length is about 9700 characters, containing substantive data on share repurchases, not merely an announcement or certification. Therefore, the appropriate classification is POS (Transaction in Own Shares).
2020-11-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2020
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31 October 2020, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share-related information. The content focuses on share capital changes and securities movements rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting share capital movements for a specific month, typical of a capital or shareholding update. Given the detailed share capital movements and the monthly frequency, this fits best under the category of Share Issue/Capital Change (SHA). The document is not an announcement of a report but the actual detailed monthly return on share capital movements, so it is not RPA or RNS. Therefore, the classification is SHA with high confidence.
2020-11-03 English
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 12 OCTOBER 2020
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement from Uni-Bio Science Group Limited regarding the poll results of an Extraordinary General Meeting (EGM) held on 12 October 2020. It details the voting outcome on a resolution to appoint a new auditor. The text includes specific voting numbers and percentages, references the notice of the EGM, and confirms the resolution was passed. The document is short (3606 characters) and focuses solely on the voting results of a shareholder meeting. It does not contain a full report, financial statements, or detailed management discussion. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2020-10-12 English

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.